Conjunctivitis As a Common Adverse Effect of Dupilumab in Atopic Dermatitis

Dupilumab is a monoclonal antibody against the α subunit of the receptor for interleukin 4 and interleukin 13.It is the first biological drug registered in the world for the treatment of atopic dermatitis.Dupilumab turned out to be a milestone in the treatment of atopic dermatitis and an alternative to standard immunosuppressive drugs.In numerous multicenter studies, including real-life studies, it has been proven that dupilumab brings a significant improvement in subjective and objective clinical symptoms in atopic dermatitis.Conjunctivitis is one of the side effects of dupilumab treatment.It is estimated that it affects about 14% of patients with atopic dermatitis.The mechanisms leading to it are not yet fully understood.